Researchers at the 22nd International Congress of the Transplantation Society today will discuss a steroid-free drug regimen for kidney transplant recipients that achieved a 7% rate of acute rejection. The research, conducted by a team at Stanford University, has spanned almost a decade and included 129 patients -- from 8 months to 22 years old, 92% of whom are still alive.

Related Summaries